Ishida T - Search Results

1

The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin-transferrin receptor 1 axis.

Kameda K, Yanagiya R, Miyatake Y, Carreras J, Higuchi H, Murayama H, Ishida T, Ito A, Iida S, Fukuhara N, Harigae H, Fujioka Y, Takahashi N, Wada H, Ishida F, Nakazawa H, Ishihara R, Murakami Y, Tagawa H, Matsuura T, Nakagawa S, Iwabuchi S, Hashimoto S, Imadome KI, Nakamura N, Ishizawa K, Kanda Y, Ando K, Kotani A. Kameda K, et al. Among authors: ishida f, ishida t. Blood. 2023 Jul 27;142(4):352-364. doi: 10.1182/blood.2022018597. Blood. 2023. PMID: 37146246

2

CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified.

Ishida T, Inagaki H, Utsunomiya A, Takatsuka Y, Komatsu H, Iida S, Takeuchi G, Eimoto T, Nakamura S, Ueda R. Ishida T, et al. Clin Cancer Res. 2004 Aug 15;10(16):5494-500. doi: 10.1158/1078-0432.CCR-04-0371. Clin Cancer Res. 2004. PMID: 15328188

3

The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma.

Ishida T, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H, Inagaki H, Okada N, Fujita T, Shitara K, Akinaga S, Takahashi T, Utsunomiya A, Ueda R. Ishida T, et al. Clin Cancer Res. 2004 Nov 15;10(22):7529-39. doi: 10.1158/1078-0432.CCR-04-0983. Clin Cancer Res. 2004. PMID: 15569983

4

Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.

Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R. Ishida T, et al. Cancer Res. 2006 Jun 1;66(11):5716-22. doi: 10.1158/0008-5472.CAN-06-0261. Cancer Res. 2006. PMID: 16740709

5

Regulatory T-cell function of adult T-cell leukemia/lymphoma cells.

Yano H, Ishida T, Inagaki A, Ishii T, Kusumoto S, Komatsu H, Iida S, Utsunomiya A, Ueda R. Yano H, et al. Among authors: ishida t. Int J Cancer. 2007 May 1;120(9):2052-7. doi: 10.1002/ijc.22536. Int J Cancer. 2007. PMID: 17278106 Free article.

6

Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome.

Yano H, Ishida T, Inagaki A, Ishii T, Ding J, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R. Yano H, et al. Among authors: ishida t. Clin Cancer Res. 2007 Nov 1;13(21):6494-500. doi: 10.1158/1078-0432.CCR-07-1324. Clin Cancer Res. 2007. PMID: 17975162

7

Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.

Yano H, Kayukawa S, Iida S, Nakagawa C, Oguri T, Sanda T, Ding J, Mori F, Ito A, Ri M, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Inagaki H, Suzuki A, Ueda R. Yano H, et al. Among authors: ishida t. Cancer Sci. 2008 Nov;99(11):2309-14. doi: 10.1111/j.1349-7006.2008.00936.x. Epub 2008 Sep 1. Cancer Sci. 2008. PMID: 18771527 Free article.

8

Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.

Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, Takino H, Mori F, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R. Ito A, et al. Among authors: ishida t. Cancer Immunol Immunother. 2009 Aug;58(8):1195-206. doi: 10.1007/s00262-008-0632-0. Epub 2008 Dec 2. Cancer Immunol Immunother. 2009. PMID: 19048251 Free PMC article.

9

Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.

Ri M, Iida S, Ishida T, Ito A, Yano H, Inagaki A, Ding J, Kusumoto S, Komatsu H, Utsunomiya A, Ueda R. Ri M, et al. Among authors: ishida t. Cancer Sci. 2009 Feb;100(2):341-8. doi: 10.1111/j.1349-7006.2008.01038.x. Cancer Sci. 2009. PMID: 19068089 Free article.

10

Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.

Inagaki A, Ishida T, Yano H, Ishii T, Kusumoto S, Ito A, Ri M, Mori F, Ding J, Komatsu H, Iida S, Ueda R. Inagaki A, et al. Among authors: ishida t. Int J Cancer. 2009 Jul 1;125(1):212-21. doi: 10.1002/ijc.24351. Int J Cancer. 2009. PMID: 19358282 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,796 results

Search Page